Figures
Concerns have been raised about discrepancies in the methods and results between this article [1] and a related thesis by the first author [2]. In response, the first author stated that the discrepancies are due to errors in [2]. The first author also provided the underlying data for this article [S1–S9 Files] and additional information on the antibodies used in [1] (Table 1). The VEGFR2 antibody details were not clarified.
A member of the Editorial Board reviewed the concerns and authors’ responses, and was satisfied with the responses, but noted that hematoxylin & eosin (H&E) staining is mentioned in the Materials and Methods in [1] but is not shown.
Supporting information
S1 File. Individual-level quantitative data underlying the tumor weight results in [1].
https://doi.org/10.1371/journal.pone.0316407.s001
(XLSX)
S2 File. Individual-level quantitative data underlying the Serum VEGF results in [1].
https://doi.org/10.1371/journal.pone.0316407.s002
(XLSX)
S3 File. Individual-level quantitative data underlying the Serum IGF-I results in [1].
https://doi.org/10.1371/journal.pone.0316407.s003
(XLSX)
S4 File. Individual-level quantitative data underlying the VEGFR2 results in [1].
https://doi.org/10.1371/journal.pone.0316407.s004
(XLSX)
S5 File. Individual-level quantitative data underlying the IGF-IR results in [1].
https://doi.org/10.1371/journal.pone.0316407.s005
(XLSX)
S6 File. Individual-level quantitative data underlying the CD31 results in [1].
https://doi.org/10.1371/journal.pone.0316407.s006
(XLSX)
S7 File. Underlying images supporting the VEGFR results in [1].
https://doi.org/10.1371/journal.pone.0316407.s007
(RAR)
S8 File. Underlying images supporting the IGFR results in [1].
https://doi.org/10.1371/journal.pone.0316407.s008
(RAR)
S9 File. Underlying images supporting the CD31 results in [1].
https://doi.org/10.1371/journal.pone.0316407.s009
(RAR)
References
- 1. Abd-Alhaseeb MM, Zaitone SA, Abou-El-Ela SH, Moustafa YM (2014) Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich’s Ascites Carcinoma: Role of Angiotensin (1–7). PLoS ONE 9(1): e85891. https://doi.org/10.1371/journal.pone.0085891 pmid:24465768
- 2.
Abd-Alhaseeb El-Mahdy MM (2010) Anti-angiogenic effect of the AT1R blocker, Olmesartan, in addition to sorafenib in in-vivo and in-vitro models of cancer. PhD thesis, Suez Canal University
Citation: The PLOS ONE Editors (2024) Editorial Note: Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich’s Ascites Carcinoma: Role of Angiotensin (1–7). PLoS ONE 19(12): e0316407. https://doi.org/10.1371/journal.pone.0316407
Published: December 19, 2024
Copyright: © 2024 The PLOS ONE Editors. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.